

7 September 2022

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir / Madam

Bod Australia Limited (ASX: BOD)
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)

Bod Australia Limited (ASX:BOD) ACN 601 225 441 (the **Company** or **Bod**) has today issued 16,875,000 shares in the Company to professional and sophisticated investors under a share placement which was announced to ASX on 1 September 2022.

The Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Act**) that:

1. the Company issued 16,875,000 ordinary shares in the Company without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice the Company has complied with:
 - a. the provisions of Chapter 2M of the Act as they apply to Bod; and
 - b. sections 674 and 674A of the Act;
3. there is no information that is 'excluded information' (within the meaning of section 708A(7) and section 708A(8) of the Act).

Authorised for release by the Company Secretary of Bod Australia Limited.

ENDS

Further Information

Investors:

Stephen Kelly
Company Secretary
Info@bodaustralia.com
+61 415 719 695

Media:

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

About Bod Australia

Bod Australia Limited (ASX:BOD) Bod is a cannabis focused drug development and product innovation company.

Bod is focused on progressing R&D and a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for the consumer and medical markets.

The company has a number of existing partnerships with large corporate groups and collaborations with leading research partners to advance the use of CBD.

For more information on BOD please visit <https://bodscience.com/>

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 T +61 2 9199 5018 E info@bodscience.com W bodscience.com

IMPORTANT INFORMATION

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state securities laws.

CONTACT

Level 1, 377 New South Road, Double Bay NSW 2028 **T** +61 2 9199 5018 **E** info@bodscience.com **W** bodscience.com